Gold prices edge up amid Fed rate cut hopes; US-Russia talks awaited
LONDON - BlackRock (NYSE:BLK), Inc., the global investment management corporation, has disclosed a significant holding in Mural Oncology plc, according to a recent filing with the Irish Takeover Panel. The disclosure, dated May 20, 2025, reveals that BlackRock now owns 1.64% of the biopharmaceutical company, which specializes in developing innovative cancer treatments.
The position comprises 283,677 ordinary shares and an additional 15 shares through cash-settled derivatives. No short positions were reported. The dealing that led to this disclosure involved the reduction of a short position in cash-settled derivatives, specifically contracts for differences (CFDs), amounting to 40,236 shares at a price of USD 2.9717 per share.
Mural Oncology has been the subject of interest due to its work in the oncology space, and this move by BlackRock signals confidence in the company’s prospects. The investment firm has not disclosed any dealings in securities of other parties related to the offer, nor has it indicated involvement with any exempt fund manager connected with Mural Oncology.
The filing with the Irish Takeover Panel is a routine disclosure required under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022, which mandates that any person with interests in relevant securities representing 1% or more must make an opening position disclosure.
Contact details provided in the press release include Jana Blumenstein, reachable at +44 20 7743 3650, for any further inquiries regarding the disclosure. This information is based on a press release statement and is intended to provide investors with the latest developments in the financial positioning of BlackRock with respect to Mural Oncology plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.